BI

Bioheng

1 known investors

bioheng.com ↗

Bioheng develops allogeneic CAR-T cell therapies for cancers and autoimmune diseases, using its Imviva platform and ANSWER technology with immune-evasion science to improve cell therapy performance and persistence. The company operates in the cell therapy and biotechnology field.

Investors · 1

DE

Decheng CapitalMenlo Park